Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled CHF 6333 in CF and NCFB
NCT04010799Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and Non-cystic fibrosis bronchiectasis (NCFB) comparing CHF 6333 with Placebo (2 arms). Primary endpoints: Adverse Event, Change in Vital Signs and 5 more. Started May 2019; status: completed.
02
Drugs
CHF-6333
03
Conditions
cystic fibrosis (CF)Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04010799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010799.